Target intelligence / Profile preview

ATP-sensitive potassium channel, pancreatic beta cell (KATP channel)

Target
KATP channel
Molecular classification
Ion channel, Potassium channel, Ligand-gated ion channel (metabolism-gated)
01

Overview

The ATP-sensitive potassium channel in pancreatic beta cells (KATP channel) is a crucial ion channel complex that links cell metabolism to electrical activity, coupling glucose metabolism with insulin secretion. The channel is a hetero-octamer composed of two key subunits: Kir6.2 (encoded by the KCNJ11 gene), which forms the potassium-selective pore, and SUR1 (encoded by the ABCC8 gene), which acts as the regulatory sulfonylurea receptor. In low-glucose states, the channel is open, hyperpolarizing the cell membrane and preventing insulin secretion. As glucose enters the cell and increases intracellular ATP, the channel closes, resulting in membrane depolarization, calcium influx through voltage-dependent calcium channels, and trigger of insulin release. Dysfunction of this channel due to gene mutations results in disorders such as congenital hyperinsulinism (channel stays closed, high insulin) and various forms of diabetes (channel stays open, low insulin)[1][2][3]. Drugs such as sulfonylureas close the channel to stimulate insulin release, while diazoxide opens it to reduce insulin secretion. The channel is a major pharmacological target for the treatment of diabetes and hyperinsulinism.

Other names
ATP-dependent potassium channelATP-sensitive potassium channelKATP channelPancreatic KATP channelPancreatic beta cell KATP channel
02

Mechanism of action

Sulfonylureas: block (inhibit) channel to stimulate insulin secretion. Diazoxide: opens (activates) the channel, inhibiting insulin secretion. Altering channel activity directly affects beta cell excitability and insulin release

03

Biological functions

Glucose sensingInsulin secretion couplingRegulation of cell membrane potentialMetabolic signalingCell excitability
04

Disease associations

Diabetes mellitus (type 2, neonatal diabetes)Congenital hyperinsulinismOther metabolic diseases related to insulin dysregulation
05

Safety considerations

Risk of hypoglycemia (from excessive channel inhibition)Risk of hyperglycemia and diabetes (from channel activation or gain-of-function mutation)Sulfonylureas can cause hypoglycemia as a side effectDiazoxide can cause hyperglycemia
06

Interacting drugs

Sulfonylureas (e.g., glibenclamide, tolbutamide)

2 more in the full profile.

07

Biomarkers

Mutations in Kir6.2 (KCNJ11) and SUR1 (ABCC8) genesSerum insulin and C-peptide levels for functional monitoringBlood glucose response to sulfonylurea therapy

Beyond the preview

Go deeper on ATP-sensitive potassium channel, pancreatic beta cell (KATP channel).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATP-sensitive potassium channel, pancreatic beta cell (KATP channel).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call